Clinical trials: active, in Haiti
Pulmonary Tuberculosis
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary…
- Trial name
- RAD-TB (NCT06192160)
- Testing
- Isoniazid, Rifampicin, Pyrazinamide
- Where
- 30 sites in Botswana, Brazil and 12 more
- Volunteers
- 315 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
This study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB).
- Trial name
- NCT07124559
- Testing
- Rifapentine, Isoniazid, Dolutegravir
- Where
- 11 sites in Botswana, Haiti and 4 more
- Volunteers
- 144 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Pulmonary, Tuberculosis Infection
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
The purpose of this study is to determine whether one or two 17-week regimens of tuberculosis treatment bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ) plus either Rifabutin (Rb) or Delamanid (D or DLM) are as…
- Trial name
- CRUSH-TB (NCT05766267)
- Testing
- Rifabutin, Delamanid, Bedaquiline
- Where
- 8 sites in United States, Canada and 4 more
- Volunteers
- 288 people
- Sponsor
- Centers for Disease Control and Prevention
HIV Infection
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
The study will explore the effects of early intensive antiretroviral therapy (ART) with or without a broadly neutralizing antibody (bNAb) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among…
- Trial name
- NCT02140255
- Testing
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r)
- Where
- 47 sites in United States, Argentina and 11 more
- Volunteers
- 1,120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
The A5414 study will evaluate whether treatment for drug-susceptible pulmonary tuberculosis (TB) can be tailored according to a participant's risk of an unfavorable outcome.
- Trial name
- NCT07595042
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 29 sites in Argentina, Australia and 14 more
- Volunteers
- 900 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Pulmonary, HIV
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis
The PRESCIENT trial is a Phase IIc, open-label, randomized trial that compared a 12-week regimen of bedaquiline (BDQ), clofazimine (CFZ), pyrazinamide (PZA), and delamanid (DLM) with standard treatment for drug-susceptible…
- Trial name
- PRESCIENT (NCT05556746)
- Testing
- Bedaquiline (BDQ), Clofazimine (CFZ), Pyrazinamide (PZA)
- Where
- 2 sites in Haiti, South Africa
- Volunteers
- 94 people
- Sponsor
- Brigham and Women's Hospital
Latent Tuberculosis
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
This study is conducted to compare the safety and effectiveness of a novel short 6-week regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of rifamycin-based treatment (standard of care…
- Trial name
- ASTERoiD (NCT03474029)
- Testing
- Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks
- Where
- 21 sites in United States, Australia and 6 more
- Volunteers
- 3,400 people
- Sponsor
- Centers for Disease Control and Prevention
Hypertension, Diabetes
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Investigators will establish a longitudinal cohort of ~3,000 adults >18 years in Port-au-Prince using multistage random sampling, and follow them longitudinally to evaluate the prevalence and incidence of cardiovascular disease…
- Conditions
- Hypertension, Diabetes, Obesity, Kidney Diseases
- Trial name
- NCT03892265
- Testing
- Observational Study
- Where
- Haiti
- Volunteers
- 3,005 people
- Sponsor
- Weill Medical College of Cornell University
Telemedicine, Pediatrics
Improving Nighttime Access to Care and Treatment; Part 4-Haiti
Children in resource-limited settings who develop illness at night are often isolated from care, resulting in progression to an emergency.
- Trial name
- INACT4-H (NCT05480930)
- Testing
- paper-based clinical decision support (dCDS) tool, digital clinical decision support (dCDS) tool
- Where
- Haiti
- Volunteers
- 7,124 people
- Sponsor
- University of Florida
Tuberculosis, MDR
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among…
- Trial name
- PHOENIx MDR-TB (NCT03568383)
- Testing
- Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
- Where
- 31 sites in Botswana, Brazil and 11 more
- Volunteers
- 5,832 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)